| Previous Close | 5.05 |
| Open | 5.27 |
| Bid | 4.70 x 900 |
| Ask | 5.82 x 1200 |
| Day's Range | 5.06 - 5.06 |
| 52 Week Range | 4.46 - 7.00 |
| Volume | 239 |
| Avg. Volume | 119 |
| Market Cap | 9.617M |
| Beta (3Y Monthly) | -0.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.64 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.60 (12.88%) |
| Ex-Dividend Date | 2019-07-11 |
| 1y Target Est | N/A |
BERKELEY HEIGHTS, N.J., May 14, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
BERKELEY HEIGHTS, N.J., May 08, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
BERKELEY HEIGHTS, N.J., April 01, 2019 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing.
– Conference Call Scheduled March 27, 2019 at 4:30 p.m. EDT – BERKELEY HEIGHTS, N.J., March 27, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel".
Penny stock Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) was sinking lower Tuesday after the nanocap biotech 's announcement concerning a paper published by independent investigators in the Journal of ...
-- PALOMA-3 study gene expression profiling shows that CDK2 is a key kinase bypass mechanism after treatment with palbociclib plus hormone therapy -- -- Cyclin E is proposed.
BERKELEY HEIGHTS, N.J., March 20, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
Cyclacel Pharmaceuticals, Inc. (CYCC) (CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it will participate in the 31st Annual ROTH Capital Partners Conference, which will be held March 18-19, 2019 at the Ritz-Carlton in Dana Point, California. For additional conference information or to schedule a one-on-one meeting with Cyclacel please email oneononerequests@roth.com or contact your ROTH representative.
BERKELEY HEIGHTS, N.J., March 05, 2019 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing.
BERKELEY HEIGHTS, N.J., Feb. 05, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
"Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2018 achievements and providing an outline of the Company’s key business objectives for 2019. “At the heart of our business strategy is targeting cancer patients with overexpression of resistance pathways, including Mcl-1, and inherited mutations in DNA damage pathways, including BRCA.
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at Biotech Showcase™ 2019, at 9:30 a.m. PST on January 8 , in the Yosemite C (Ballroom level) at the Hilton San Francisco Union Square. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs. A live webcast of the presentation will be available through the Company's website: www.cyclacel.com.
Conference Call Scheduled November 12, 2018 at 4:30 p.m. ET BERKELEY HEIGHTS, N.J., Nov. 12, 2018 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or.
BERKELEY HEIGHTS, N.J., Nov. 06, 2018 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing.